A barbiturate drug test, commonly labeled BAR on a test panel, screens for a class of sedative medications that includes phenobarbital and butalbital along with several older prescription and surgical agents. Most immunoassay BAR panels report a positive screen at or above 300 ng/mL in urine, and the specific barbiturate involved affects the detection window far more than the test method does. A single dose of a short acting barbiturate typically clears a urine screen within a few days, while phenobarbital, the longest acting barbiturate still in common medical use, can remain detectable for two to four weeks or longer with regular dosing.
What Counts as a Barbiturate, and Which Ones Are Still in Use
Barbiturates are central nervous system depressants that were the dominant sedative and sleep medication class for much of the twentieth century before benzodiazepines largely replaced them for anxiety and insomnia. Three groups of barbiturates still show up in clinical practice today, and by extension on drug test panels.
Phenobarbital remains an active anti-seizure medication. The National Institutes of Health notes that phenobarbital "has multiple clinical uses that include anti-seizure management," and that it also plays a role in status epilepticus and in the management of benzodiazepine and alcohol withdrawal (NIH/NLM, StatPearls, Phenobarbital).
Butalbital continues to circulate mainly in headache combination products, usually paired with acetaminophen and caffeine. Federal drug labeling for one such product states it is "indicated for the relief of the symptom complex of tension (or muscle contraction) headache" (NIH/NLM, DailyMed, butalbital, acetaminophen, and caffeine label). The National Institutes of Health also notes that "the combination of butalbital and acetaminophen is approved for relieving symptoms associated with tension-type headaches" (NIH/NLM, StatPearls, Barbiturates).
Short acting and ultra short acting barbiturates, including secobarbital, pentobarbital, thiopental, and methohexital, see far more limited use today, mostly in veterinary sedation and euthanasia, select anesthesia settings, and historically as sleep aids. Ultra short acting agents such as thiopental and methohexital are given intravenously and used as anesthetics, while short and intermediate acting agents such as pentobarbital and secobarbital have durations of effect of about two to six hours and were historically used as sleeping aids and sedatives (NIH/NLM, StatPearls, Barbiturate Toxicity).
Because they carry real dependence potential, several barbiturates remain federally controlled substances. Pentobarbital and secobarbital are listed among the Schedule II barbiturate examples in the National Institutes of Health's overview of DEA drug scheduling, a schedule reserved for substances with "high abuse potential with severe psychological or physical dependence" (NIH/NLM, StatPearls, DEA Drug Scheduling; DEA, Controlled Substance Schedules). Lower scheduled barbiturates such as butalbital and phenobarbital still carry documented dependence and withdrawal risk, which is part of why programs that manage people through withdrawal or chronic pain keep BAR on their testing menu rather than treating it as an optional add-on.
BAR Panel Cutoffs: What Counts as a Positive Screen
A BAR test is an immunoassay, the same basic screening technology used for THC, opiate, or amphetamine panels. It reports a positive result when the barbiturate concentration in a urine specimen reaches or exceeds the device's cutoff, most commonly set at 300 ng/mL for point of care cups, dip cards, and cassettes. That initial result is presumptive, not final. As the National Library of Medicine explains in its overview of drug testing, "if you have a positive test result, you'll usually have a follow-up urine test to make sure the first test was correct," using "a more sensitive test that provides more accurate results" (NIH/NLM, MedlinePlus, Drug Testing). For barbiturates, that follow up is a laboratory confirmation run by gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry, typically at a lower, drug specific cutoff than the screening device used.
Detection Windows by Duration Class
How long a barbiturate stays detectable tracks its elimination half-life, the time it takes the body to clear half the drug from the bloodstream. Barbiturates have historically been grouped by how long their effects last, from ultra short acting anesthetics to long acting anti-seizure medications, and that same grouping is a useful shorthand for detection windows, even though actual clearance depends on dose, frequency of use, kidney and liver function, urine concentration, and the specific screening cutoff applied. The National Institutes of Health describes durations of effect of roughly two to six hours for short and intermediate acting barbiturates such as pentobarbital and secobarbital, and greater than six hours for long acting barbiturates such as phenobarbital (NIH/NLM, StatPearls, Barbiturate Toxicity).
| Duration Class | Example Drugs | Reported Plasma Half-Life | Approximate Single-Dose Urine Detection Window |
|---|---|---|---|
| Short-acting | Secobarbital, pentobarbital | Secobarbital: 15 to 40 hours, mean 28; pentobarbital: 15 to 50 hours, dose dependent | Roughly 1 to 4 days |
| Intermediate-acting | Butalbital, amobarbital | Butalbital: about 35 hours | Roughly 3 to 7 days, longer with repeated headache-combination dosing |
| Long-acting | Phenobarbital | 53 to 118 hours, mean 79, in adults | Roughly 2 to 4 or more weeks, especially with chronic or daily dosing |
Half-life figures are drawn from federal drug labeling for secobarbital, pentobarbital, and phenobarbital (NIH/NLM, DailyMed, secobarbital sodium label; NIH/NLM, DailyMed, pentobarbital sodium label; NIH/NLM, DailyMed, phenobarbital label) and for butalbital in an acetaminophen and caffeine combination product (NIH/NLM, DailyMed, butalbital, acetaminophen, and caffeine label). Detection windows are general estimates built from those half-life ranges and typical screening cutoffs. They are not guarantees for any individual result, and repeated or chronic dosing of any barbiturate can extend the window well beyond a single dose estimate.
Why Treatment Programs and Pain Management Clinics Keep BAR on the Panel
Not every drug test menu includes BAR by default. Standard test configurations are usually built around a narrower set of drug classes, which means an employer, clinic, or program that wants barbiturate coverage typically has to select a cup, dip card, or laboratory panel that lists BAR as one of its printed analytes rather than assuming it is already included.
Two buyer groups request BAR most consistently, and both align with the medical uses described above. Addiction recovery and treatment programs monitor for barbiturate misuse or diversion, particularly where phenobarbital itself is used as a taper medication for alcohol or benzodiazepine withdrawal, so a non-negative result needs to be read against what the treatment plan actually prescribes rather than assumed to be illicit use. Programs managing this population commonly build panel configurations from ASC's addiction recovery drug and alcohol testing collection, and treatment centers more broadly can review ASC's rehabilitation and addiction treatment center drug testing collection.
Pain management clinics that prescribe butalbital combination products for chronic tension headache need a way to confirm patients are taking the medication as directed and not diverting it, which is why pain management and pain clinic testing programs commonly add BAR to their standard panel instead of treating it as optional. Configurations built for this setting are available in ASC's pain management and pain clinic drug testing collection.
Corrections, probation, and some safety sensitive employers also add BAR when their tested population has a documented history of sedative misuse, though coverage varies from program to program and should be matched to the population actually being monitored.
Choosing Test Products with BAR Coverage
Because BAR is not automatically bundled into every configuration, buyers should confirm the printed analyte list on any device before assuming barbiturate coverage is included. ASC's drug testing cups and drug test dip card collections both include configurations with BAR as a selectable analyte alongside standard drugs of abuse, so a program can match the panel to the population it actually tests rather than defaulting to a generic configuration that never included barbiturates in the first place.
Confirmation and Clinical Review of Prescriptions
A non-negative immunoassay screen is a screening result, not a diagnosis, and it is not proof of illicit use on its own. Legitimate phenobarbital prescriptions for seizure disorders and butalbital combination prescriptions for tension headache can both produce a non-negative BAR screen. Consistent with the general confirmation process described by the National Library of Medicine, best practice is to confirm any non-negative screen at a certified laboratory and have a medical review officer, treatment provider, or other qualified reviewer check the result against the individual's documented medication history before any employment, clinical, or program decision is made. Laboratories and clinics building out that confirmation capability can review ASC's drug test kits for laboratories collection.
Related reading
This article is for general educational purposes and does not constitute medical, legal, or employment advice. Drug and alcohol test screening devices, including BAR panels, provide presumptive results only; they detect the presence or absence of a substance above a stated cutoff and do not diagnose a medical condition, confirm intent, or identify a specific individual's pattern of use. Any non-negative screening result should be confirmed by an appropriately accredited laboratory and reviewed by a qualified medical review officer or clinician with access to the individual's prescription history before any adverse action is taken. Testing programs should consult applicable federal, state, and local regulations and their own legal counsel when designing a testing policy.
Frequently Asked Questions
How long do barbiturates stay in urine?
It depends on which barbiturate was used. Short acting barbiturates such as secobarbital and pentobarbital are generally detectable for about 1 to 4 days after a single dose, intermediate acting butalbital for roughly 3 to 7 days, and long acting phenobarbital for about 2 to 4 or more weeks, especially with regular dosing. These are estimates based on published half-life ranges, not guarantees for any individual result.
What cutoff level does a BAR drug test use?
Most point of care BAR immunoassay panels, including cups and dip cards, screen positive at or above 300 ng/mL in urine. A non-negative screen should be confirmed at a certified laboratory using gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry, typically at a lower, drug specific cutoff.
Will a legitimate phenobarbital or butalbital prescription cause a positive barbiturate test?
Yes, a prescribed and appropriately dosed barbiturate, such as phenobarbital for a seizure disorder or a butalbital combination product for tension headache, can produce a non-negative BAR screen. That is why any non-negative result should be confirmed by a laboratory and reviewed by a medical review officer or clinician who can check it against the individual's documented prescriptions.
Why isn't BAR included on every standard drug test panel?
Barbiturates are not part of every standard drug testing menu, so BAR coverage typically has to be selected as a printed analyte on a specific cup, dip card, or laboratory panel. Programs that regularly encounter barbiturate use, including addiction treatment programs monitoring withdrawal medications and pain clinics managing butalbital headache prescriptions, are the buyers most likely to add BAR by default.
